Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 31 of the 53 sources its claims cite were checked for support.

Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients

Open access
Sorenson, Christine M., Gurel, Zafer, Song, Yong-Seok, Peterson, Kyle D., Blodi, Barbara A., Sheibani, Nader · 2024 · PLOS ONE

Abstract

Age-related macular degeneration (AMD) is a vision threatening disease in older adults. Anti-VEGF treatment is effective for the majority of neovascular AMD (nAMD) patients, although approximately 30% of nAMD patients have an incomplete response for unknown reasons. Here we assessed the contribution of single nucleotide polymorphisms (SNPs) in key angioinflammatory regulatory genes in nAMD patients with an incomplete response compared to those responsive to anti-VEGF treatment. A total of 25 responsive and 30 nAMD patients with an incomplete response to anti-vascular endothelial growth factor (anti-VEGF) treatment were examined for known SNPs that impact the structure and function of thromobospondin-1 (TSP1), Bcl-2-interacting mediator of cell death (BIM) and complement factor H (CFH). Plasma levels of C-C motif chemokine ligand 2 (CCL2/MCP1), TSP1 and VEGF were assessed by ELISA. Patients responsive to anti-VEGF treatment showed a significant increase in the TSP1 rs2228262 AA allele and a trend for the BIM (rs724710) CT allele. Consistent with previous reports, 42% of the patients responsive to anti-VEGF expressed the CC allele for CFH rs1061170. Although the CFH TT allele had similarly low prevalence in both groups, the TC allele tended to be more prevalent in patients with an incomplete response. Patients with an incomplete response also had increased plasma CCL2/MCP1 levels, consistent with the role increased inflammation has in the pathogenesis of nAMD. Our studies point to new tools to assess the potential responsiveness of nAMD patients to anti-VEGF treatment and suggest the potential use of anti-CCL2 for treatment of nAMD patients with an incomplete response to anti-VEGF.

Overview

CoChat Summary

TL;DR

In nAMD patients, the TSP1 rs2228262 AA allele was significantly more frequent among anti-VEGF responders, while incomplete responders had higher plasma CCL2/MCP1. The authors suggest TSP1/BIM/CFH polymorphisms and CCL2/MCP1 may help assess anti-VEGF responsiveness and that anti-CCL2 therapy warrants study.

Key findings

  • TSP1 rs2228262 AA allele was significantly increased in responsive patients: 88% (22/25) vs 67% (20/30) in incomplete responders; no responsive patient had the GG allele. The odds of response were 5-fold greater for homozygous wildtype A carriers (OR = 5.00, 95% CI 1.03–32.00; PD = 0.97), with 68% (95% CI 37%–89%) vs 31% (95% CI 8%–63%) estimated to respond.
  • BIM rs724710 showed a trend: the CT allele was more common in responders (53% vs 30%), while incomplete responders tended to have the CC allele. Homozygous CC had lower odds of response (OR = 0.41, 95% CI .012–1.30; PD = 0.93).
  • CFH rs1061170 CC was present in 42% of responsive patients vs 33% of incomplete responders; TT prevalence was similarly low in both groups, and TC tended to be more prevalent in incomplete responders.
  • Incomplete responders had significantly increased plasma CCL2/MCP1; VEGF trended higher but did not reach significance, and TSP1 plasma levels were similar between groups. Choroidal endothelial cells lacking TSP1 showed increased CCL2/MCP1, IL6, and IL1β expression.

Methods

  • Blood samples from 25 anti-VEGF-responsive and 30 incomplete-response nAMD patients were genotyped for TSP1 rs1478604 and rs2228262, BIM rs724710, and CFH rs1061170 by Sanger sequencing or TaqMan qPCR. Responsiveness was defined by absence of intraretinal/subretinal fluid on OCT after 1 year; incomplete response by persistent fluid after 1 year.
  • Plasma CCL2/MCP1, VEGF, and TSP1 were measured by ELISA. Murine wild-type and TSP1−/− choroidal endothelial cells were analyzed by qPCR for MCP-1, IL-6, and IL-1β.
  • Genetic associations used dominant, recessive, and co-dominant models with Bayesian logistic regression, reporting odds ratios, 95% highest density credible intervals, and probability of direction; sensitivity analysis used Jensen-Shannon distance.

Limitations

  • The paper states the study had a moderate sample size, took place during the COVID pandemic which restricted patient access and participation, and that sex and age covariates were removed due to sub-optimal model fit.
  • The paper states that TSP1 rs2228262 recessive and co-dominant models showed prior sensitivity with low likelihood sensitivity, indicating not enough observations for reliable comparisons in those models.
  • Evident from the text: many findings are trends rather than significant associations, the cohort is small and from a single Wisconsin clinic, and no replication cohort is reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0297135

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 TSP1, BIM, and CFH prominence in nAMD patients both responsive and those with an incomplete response to anti-VEGF therapy. DNA was sequenced from nAMD patients responsive and those with an incomplete response to anti-VEGF therapy for TSP1 rs1478604 and rs2228262, BIM rs724710 and CFH rs1061170. The allele genotypes for responsive and those with an incomplete response are noted in color in the key on the left. Please note that patients with TSP1 rs2228262 AA allele were significantly increased in patients responsive to treatment.
Fig 1 TSP1, BIM, and CFH prominence in nAMD patients both responsive and those with an incomplete response to anti-VEGF therapy. DNA was sequenced from nAMD patients responsive and those with an incomplete response to anti-VEGF therapy for TSP1 rs1478604 and rs2228262, BIM rs724710 and CFH rs1061170. The allele genotypes for responsive and those with an incomplete response are noted in color in the key on the left. Please note that patients with TSP1 rs2228262 AA allele were significantly increased in patients responsive to treatment.CC BY · PubMed Central
Fig 2 Increased CCL2/MCP-1 levels in patients with an incomplete response. Patient plasma levels of CCL2/MCP-1, VEGF and TSP1 were assessed by ELISA. Levels were assessed in patients responsive (R) and those with an incomplete response (IR) to anti-VEGF therapy. Please note that patients with an incomplete response to therapy had significantly increased CCL2/MCP-1 levels. (*P<0.05; n≤15; Student’s unpaired t-test (2-tailed) was utilized).
Fig 2 Increased CCL2/MCP-1 levels in patients with an incomplete response. Patient plasma levels of CCL2/MCP-1, VEGF and TSP1 were assessed by ELISA. Levels were assessed in patients responsive (R) and those with an incomplete response (IR) to anti-VEGF therapy. Please note that patients with an incomplete response to therapy had significantly increased CCL2/MCP-1 levels. (*P<0.05; n≤15; Student’s unpaired t-test (2-tailed) was utilized).CC BY · PubMed Central
Fig 3 Increased inflammatory mediators TSP1-/- choroidal endothelial cells. The expression levels of various inflammatory mediators were assessed by qPCR analysis for MCP-1, IL-6 and Il-1b. These experiments were repeated three times with two different isolations of murine choroidal endothelial cells with similar results. Please note a significant increase in the levels of MCP-1 and IL6 (*P<0.05; **P <0.01; n = 6; Student’s unpaired t-test (2-tailed) was utilized). RpL13A, 60S ribosomal protein L13a.
Fig 3 Increased inflammatory mediators TSP1-/- choroidal endothelial cells. The expression levels of various inflammatory mediators were assessed by qPCR analysis for MCP-1, IL-6 and Il-1b. These experiments were repeated three times with two different isolations of murine choroidal endothelial cells with similar results. Please note a significant increase in the levels of MCP-1 and IL6 (*P<0.05; **P <0.01; n = 6; Student’s unpaired t-test (2-tailed) was utilized). RpL13A, 60S ribosomal protein L13a.CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 1 Not valid · 7 Not checked · 57 Own results and interpretations

37 more claims · 5 with their cited sources checked

Create a free account to see all 88 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 25
  • It may state two separate claims as one. 27

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 51 references

Cited by

See all 5

Metadata

Authors
Sorenson, C. M., Gurel, Z., Song, Y.-S., Peterson, K. D., Blodi, B. A., & Sheibani, N.
Affiliations
University of Wisconsin–Madison (US)
Corresponding author
Sorenson, Christine M.
Venue
PLOS ONE
Published
2024-02-26
Volume
19
Issue
2
Pages
e0297135
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4392160831
Cited by
5
References
51
Citations by year
2026: 2 · 2025: 1 · 2024: 2
FWCI
1.97
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • ICTR
  • UW Center for Human Genomics and Precision Medicine
  • Pat and Jay Smith Macular degeneration treatment innovation program
  • Research to Prevent Blindness
  • Retina Research Foundation
  • NIH (P30 CA014520, EY030076, P30EY016665)
  • Lions Gift of Sight (Wisconsin)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
neovascular age-related macular degeneration, thrombospondin-1, building information modeling, complement factor H, single nucleotide polymorphisms, inflammation, genetic susceptibility, vascular endothelial growth factor
MeSH terms
Aged, Humans, Visual Acuity, Complement Factor H, Thrombospondins, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide, Vascular Endothelial Growth Factor A, Wet Macular Degeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients. https://app.cochat.ai/papers/10.1371/journal.pone.0297135
The paper
Sorenson, C. M., Gurel, Z., Song, Y.-S., Peterson, K. D., Blodi, B. A., & Sheibani, N. (2024). Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0297135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.